Whereas most of former approaches are better suited to block ligand-mediated c-Met activity, small-molecule c-Met inhibitors offer the most versatile approach by inhibiting HGF-dependent cancers as well as tumors driven by other Met-dependent mechanisms, such as receptor amplification and activating mutations [14]. Here, MET is linked to cancer.